TheraQuest's IND For Abuse Deterrent Strong Opioid (TQ-1015) Accepted By FDA (Medical News Today)
TheraQuest Biosciences, Inc. a development stage pain management company announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using SECUREL(R), TheraQuest's proprietary abuse deterrent technology.

TNFerade Receives FDA Fast Track Designation For Treatment Of Pancreatic Cancer (Medical News Today)
GenVec, Inc. (Nasdaq:GNVC) announced today that TNFerade has been granted Fast Track product designation by the U.S. Food and Drug Administration (FDA) for its proposed use in the treatment of locally advanced pancreatic cancer. The designation is based on GenVec having "provided evidence of the potential to improve survival in patients with pancreatic cancer.